Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis

The University of Texas Health Science Center at San Antonio

Overview

This is a simple tissue collection study with no therapeutic intent. Colon tissues will be taken from standard of care procedures. Tissues will be tested for their functions, expression of immune co-signaling molecules and reactions to transduction with recombinant Listeria vectors to assess effects on expression of B7-H1 and cytokines.

Study Type

OBSERVATIONAL

Conditions

Colon Cancer Colitis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Able to provide informed consent (or have consent provided through a guardian) * No immune-modulating drug use during study or within 30 days prior to enrollment * Having colon material collected as part of standard of care Exclusion Criteria: * Unable to provide informed consent (or have consent provided through a guardian) * Not having colon material collected as part of standard of care

Locations (1)

Cancer Therapy & Research Center at UTHSCSA

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Expression of B7-H1

To assess the ability of recombinant Listeria to modulate B7-H1 in human colonic tissues

Time frame: Baseline tissue collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.